Recently, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) target therapy (Gefitinib/Irresa®) oriented examination of EGFR mutations, performed on the enriched single non-small cell lung cancer CTCs [63], and NGS-guided in vitro drug screening carried out on the cultured metastatic breast cancer cells enriched from patient’s cerebrospinal fluid by SE, to successfully select the chemotherapeutic agent palbociclib (the synthetic CDK4/6 inhibitor) upon the identification of a single nucleotide variant (SNV), have been reported [64]. This evidence concerns the gene EGFR and breast carcinoma.